Zheng Wu

Zheng Wu

Auto-generated profile, based on publicly available information

Zheng Wu

Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
DBDivya Bezwada
Divya Bezwada
LPLuigi Perelli
Luigi Perelli
NLNicholas P. Lesner
Nicholas P. Lesner
LCLing Cai
Ling Cai
BBBrooks Bailey
Brooks Bailey
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Most kidney cancers are metabolically dysfunctional1–4, but how this dysfunction affects cancer progression in humans is unknown. We infused 13C-labelled nutrients in over 80 patients with kidney cancer during surgical tumour resection. Labelling from [U-13C]glucose varies across subtypes, indicating that the kidney environment alone cannot account for all tumour metabolic reprogramming. Compared with the adjacent kidney, clear cell renal cell carcinomas (ccRCCs) display suppressed labelling of tricarboxylic acid (TCA) cycle intermediates in vivo and in ex vivo organotypic cultures, indicating that suppressed labelling is tissue intrinsic. [1,2-13C]acetate and [U-13C]glutamine infusions in patients, coupled with measurements of respiration in isolated human kidney and tumour mitochondria, reveal lower electron transport chain activity in ccRCCs that contributes to decreased oxidative and enhanced reductive TCA cycle labelling. However, ccRCC metastases unexpectedly have enhanced TCA cycle labelling compared with that of primary ccRCCs, indicating a divergent metabolic program during metastasis in patients. In mice, stimulating respiration or NADH recycling in kidney cancer cells is sufficient to promote metastasis, whereas inhibiting electron transport chain complex I decreases metastasis. These findings in humans and mice indicate that metabolic properties and liabilities evolve during kidney cancer progression, and that mitochondrial function is limiting for metastasis but not growth at the original site.

9 December 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
ZWZheng Wu
Zheng Wu
Sebastian OeckSebastian Oeck
Sebastian Oeck
PWPhillip West
Phillip West
KMKailash C. Mangalhara
Kailash C. Mangalhara
ASAlva G. Sainz
Alva G. Sainz
GSGerald S. Shadel
Gerald S. Shadel

3 June 2022 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
WHWilliam Hancock-Cerutti
William Hancock-Cerutti
ZWZheng Wu
Zheng Wu
PXPeng Xu
Peng Xu
NYNarayana Yadavalli
Narayana Yadavalli
MLMarianna Leonzino
Marianna Leonzino
PCPietro De Camilli
Pietro De Camilli
Mutations in VPS13C cause early-onset, autosomal recessive Parkinson’s disease (PD). We have established that VPS13C encodes a lipid transfer protein localized to contact sites between the ER and late endosomes/lysosomes. In the current study, we demonstrate that depleting VPS13C in HeLa cells causes an accumulation of lysosomes with an altered lipid profile, including an accumulation of di-22:6-BMP, a biomarker of the PD-associated leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. In addition, the DNA-sensing cGAS-STING pathway, which was recently implicated in PD pathogenesis, is activated in these cells. This activation results from a combination of elevated mitochondrial DNA in the cytosol and a defect in the degradation of activated STING, a lysosome-dependent process. These results suggest a link between ER-lysosome lipid transfer and innate immune activation in a model human cell line and place VPS13C in pathways relevant to PD pathogenesis.

2 September 2022 in Science Advances
Verified
Journal Article
Open access
PPPanayotis Pachnis
Panayotis Pachnis
ZWZheng Wu
Zheng Wu
BFBrandon Faubert
Brandon Faubert
ATAlpaslan Tasdogan
Alpaslan Tasdogan
WGWen Gu
Wen Gu
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
In mice and humans with cancer, intravenous 13 C-glucose infusion results in 13 C labeling of tumor tricarboxylic acid (TCA) cycle intermediates, indicating that pyruvate oxidation in the TCA cycle occurs in tumors. The TCA cycle is usually coupled to the electron transport chain (ETC) because NADH generated by the cycle is reoxidized to NAD + by the ETC. However, 13 C labeling does not directly report ETC activity, and other pathways can oxidize NADH, so the ETC’s role in these labeling patterns is unverified. We examined the impact of the ETC complex I inhibitor IACS-010759 on tumor 13 C labeling. IACS-010759 suppresses TCA cycle labeling from glucose or lactate and increases labeling from glutamine. Cancer cells expressing yeast NADH dehydrogenase-1, which recycles NADH to NAD + independently of complex I, display normalized labeling when complex I is inhibited, indicating that cancer cell ETC activity regulates TCA cycle metabolism and 13 C labeling from multiple nutrients.

11 December 2025 in Science
Verified
Journal Article
Closed access
ZWZheng Wu
Zheng Wu
PNPhong T. Nguyen
Phong T. Nguyen
VSVarun Sondhi
Varun Sondhi
RYRunwen Yao
Runwen Yao
ZLZhifang Lu
Zhifang Lu
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Cells generate purine nucleotides through de novo purine biosynthesis (DNPB) and purine salvage. Purine salvage represses DNPB to prevent excessive purine nucleotide synthesis through mechanisms that are incompletely understood. We identified Nudix hydrolase 5 (NUDT5) as a DNPB regulator. During purine salvage, NUDT5 suppresses DNPB independently of its catalytic function but rather through interaction with phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme in the DNPB pathway. The NUDT5-PPAT interaction promoted PPAT oligomerization, suppressed PPAT’s enzymatic activity, and facilitated disassembly of the purinosome, a metabolon that functions in DNPB. Disrupting the NUDT5-PPAT interaction overcame DNPB suppression during purine salvage, permitting excessive DNPB and inducing thiopurine resistance. Therefore, NUDT5 governs the balance between DNPB and salvage to maintain appropriate cellular purine nucleotide concentrations.

7 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDivya Bezwada
Divya Bezwada
NLNicholas P. Lesner
Nicholas P. Lesner
BBBrooks Bailey
Brooks Bailey
DVDanny Vu
Danny Vu
ZWZheng Wu
Zheng Wu
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Summary: Most kidney cancers display evidence of metabolic dysfunction 1–4 but how this relates to cancer progression in humans is unknown. We used a multidisciplinary approach to infuse 13 C-labeled nutrients during surgical tumour resection in over 70 patients with kidney cancer. Labeling from [U- 13 C]glucose varies across cancer subtypes, indicating that the kidney environment alone cannot account for all metabolic reprogramming in these tumours. Compared to the adjacent kidney, clear cell renal cell carcinomas (ccRCC) display suppressed labelling of tricarboxylic acid (TCA) cycle intermediates in vivo and in organotypic slices cultured ex vivo, indicating that suppressed labeling is tissue intrinsic. Infusions of [1,2- 13 C]acetate and [U- 13 C]glutamine in patients, coupled with respiratory flux of mitochondria isolated from kidney and tumour tissue, reveal primary defects in mitochondrial function in human ccRCC. However, ccRCC metastases unexpectedly have enhanced labeling of TCA cycle intermediates compared to primary ccRCCs, indicating a divergent metabolic program during ccRCC metastasis in patients. In mice, stimulating respiration in ccRCC cells is sufficient to promote metastatic colonization. Altogether, these findings indicate that metabolic properties evolve during human kidney cancer progression, and suggest that mitochondrial respiration may be limiting for ccRCC metastasis but not for ccRCC growth at the site of origin.